Blood screening determines a person’s eligibility to donate blood. From first-generation ELISA to advanced NAT (nucleic acid tests) technologies, this market has witnessed technological advancements.
According to a recently published Markets and Markets research report, the blood screening market is expected to reach $2.55 billion by 2019 from $1.5 billion in 2014, with at a CAGR of 10.4% over the period. The study holds the following factors responsible for growth of the market
- Rising number of blood donations and blood donors
- Increased awareness about safety of donated blood
- Growing demand for donated blood
- increasing affordability to pay for nucleic acid testing (NAT)
- Increasing prevalence/incidence of infectious diseases
The report segments the market on the basis of products and services, technologies, end users and regions. The prominent players in the market are identified as Grifols (Spain), Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthcare (Germany), Ortho Clinical Diagnostics, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.) and Beckman Coulter (U.S.). While the North American region accounts for the largest share of the market in 2014, the Asian market is growing at the fastest rate.
In the U.S., the Centers for Disease Control and Prevention (CDC) is one of the government agencies responsible for assuring the safety of blood supply in the country. The Food and Drug Administration (FDA) regulates the collection of blood donations as well as for the manner in which blood is transfused. Each donor is screened for risk of infectious disease by questionnaire, and each unit of blood donated is screened for various infectious disease pathogens including human immunodeficiency virus (HIV) and hepatitis B and C viruses which are transmitted via transfusion, using nine laboratory tests.